{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:41:47Z","timestamp":1792510907033,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.maturitas.2026.108881","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:16:02Z","timestamp":1771402562000},"page":"108881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cardiovascular and musculoskeletal health in breast cancer survivors."],"prefix":"10.1016","volume":"207","author":[{"given":"Halle C.F.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.maturitas.2026.108881_bb0005","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.maturitas.2026.108881_bb0010","article-title":"Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the United States","volume":"6","author":"M","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.maturitas.2026.108881_bb0015","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/eurjpc\/zwad243","article-title":"Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis","volume":"30","author":"Galimzhanov","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"14","key":"10.1016\/j.maturitas.2026.108881_bb0020","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/cncr.34224","article-title":"Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study","volume":"128","author":"Koric","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108881_bb0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clbc.2019.04.012","article-title":"Personalized decision making in early stage breast cancer: applying clinical prediction models for anthracycline cardiotoxicity and breast cancer mortality demonstrates substantial heterogeneity of benefit-harm trade-off","volume":"19","author":"Upshaw","year":"2019","journal-title":"Clin. Breast Cancer"},{"issue":"35","key":"10.1016\/j.maturitas.2026.108881_bb0030","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","volume":"35","author":"Ganz","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.maturitas.2026.108881_bb0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against human epidermal growth factor receptor 2 for metastatic breast cancer that overexpresses human epidermal growth factor receptor 2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.maturitas.2026.108881_bb0040","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.maturitas.2026.108881_bb0045","article-title":"Emerging cardiovascular toxicity associated with CDK4\/6 inhibitors: real-world insights from the FDA adverse event reporting system","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"24","key":"10.1016\/j.maturitas.2026.108881_bb0050","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108881_bb0055","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaccao.2024.08.006","article-title":"Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors","volume":"6","author":"Polter","year":"2024","journal-title":"JACC CardioOncol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108881_bb0060","first-page":"577","article-title":"Cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early oestrogen receptor-positive breast cancer: a systematic review","volume":"21","author":"Gue","year":"2024","journal-title":"Arch. Med. Sci."},{"issue":"22","key":"10.1016\/j.maturitas.2026.108881_bb0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108881_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","article-title":"Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels","volume":"12","author":"Bertelli","year":"1988","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108881_bb0075","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdw673","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Khosrow-Khavar","year":"2017","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.maturitas.2026.108881_bb0080","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/heartjnl-2020-317510","article-title":"Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors","volume":"107","author":"Matthews","year":"2021","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2026.108881_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2021.07.004","article-title":"Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study","volume":"59","author":"Sund","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-023-06997-x","article-title":"Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer","volume":"201","author":"Rillamas-Sun","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"9217","key":"10.1016\/j.maturitas.2026.108881_bb0100","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(00)02263-7","article-title":"Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semradonc.2015.09.003","article-title":"Contemporary Breast Radiotherapy and Cardiac Toxicity","volume":"26","author":"Yeboa","year":"2016","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.maturitas.2026.108881_bb0110","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines in caridio-oncoloy developed in collaboration with the European Hematology Association, the European Society for Therpeutic Radiology and Oncology and the International Cardio-Oncology Society","volume":"2022","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.maturitas.2026.108881_bb0115","author":"National Comprehensive Cancer Network"},{"issue":"8","key":"10.1016\/j.maturitas.2026.108881_bb0120","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/jnci\/djae107","article-title":"Long-term cardiovascular disease risk after anthracycline and trastuzumab treatment in US breast cancer survivors","volume":"116","author":"Vo","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2026.108881_bb0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.15420\/ecr.2025.26","article-title":"Advances in cardioprotection strategies: Focusing on breast cancer and beyond through novel biomarkers and pharmacological approaches","volume":"20","author":"Tamburrini","year":"2025","journal-title":"European Cardiology Review"},{"issue":"12","key":"10.1016\/j.maturitas.2026.108881_bb0130","first-page":"846","article-title":"Combined lifestyle factors on mortality and cardiovascular disease among cancer survivors: a systematic review and meta-analysis of cohort studies","volume":"32","author":"Zhu","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.maturitas.2026.108881_bb0135","article-title":"Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study","author":"Jung","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2026.108881_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1259292","article-title":"Changes in body composition and subsequent cardiovascular disease risk among 5-year breast cancer survivors","volume":"10","author":"Kim","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.maturitas.2026.108881_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2023.10.004","article-title":"Higher diet quality relates to better cardiac function in cancer survivors: The multi-ethnic study of atherosclerosis","volume":"81","author":"Bellissimo","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108881_bb0150","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae013","article-title":"Diet quality and cardiovascular disease risk among breast cancer survivors in the Pathways Study","volume":"8","author":"Ergas","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-021-06140-8","article-title":"Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors","volume":"188","author":"Kim","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108881_bb0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.52082\/jssm.2024.366","volume":"23","author":"Al-Mhanna","year":"2024","journal-title":"J. Sports Sci. Med."},{"key":"10.1016\/j.maturitas.2026.108881_bb0165","first-page":"11","article-title":"Exercise and cardiovascular health among breast cancer survivors: a scoping review of current observational evidence","author":"Wilson","year":"2025","journal-title":"Cardio-Oncol."},{"issue":"14","key":"10.1016\/j.maturitas.2026.108881_bb0170","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.maturitas.2026.108881_bb0175","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisd\u00f3ttir","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.maturitas.2026.108881_bb0180","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108881_bb0190","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.maturitas.2026.108881_bb0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2024.08.008","article-title":"Postmenopausal osteoporosis, A review of latest guidelines","volume":"53","author":"Subarajan","year":"2024","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11764-021-00993-0","article-title":"A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting","volume":"17","author":"Kwan","year":"2023","journal-title":"J. Cancer Surviv."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jsams.2021.08.008","article-title":"The effect of exercise for improving bone health in cancer survivors - A systematic review and meta-analysis","volume":"25","author":"Singh","year":"2022","journal-title":"J. Sci. Med. Sport"},{"issue":"31","key":"10.1016\/j.maturitas.2026.108881_bb0210","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.maturitas.2026.108881_bb0215","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108881_bb0220","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"issue":"10001","key":"10.1016\/j.maturitas.2026.108881_bb0225","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108881_bb0230","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108881_bb0235","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2026.108881_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713700","article-title":"Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management","volume":"12","author":"Hyder","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.maturitas.2026.108881_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713700","article-title":"Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management","volume":"12","author":"Hyder","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0250","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-022-01576-2","article-title":"The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health","volume":"24","author":"Ballinger","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108881_bb0255","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-022-06741-x","article-title":"Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer","volume":"196","author":"Aleixo","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108881_bb0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12282-022-01401-w","article-title":"Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer","volume":"30","author":"Aleixo","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.maturitas.2026.108881_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/sports8060080","article-title":"Cardiovascular consequences of skeletal muscle impairments in breast cancer","volume":"8","author":"Zieff","year":"2020","journal-title":"Sports"},{"issue":"12","key":"10.1016\/j.maturitas.2026.108881_bb0270","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:56:17Z","timestamp":1792508177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":54,"alternative-id":["S0378512226000587"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108881","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and musculoskeletal health in breast cancer survivors.","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108881"}}